Abzu was mentioned this May in an article by the Oligonucleotide Therapeutics Society, a US non-profit dedicated to foster academia and industry-based R&D in oligonucleotide therapeutics.

“This is of great importance to us at Abzu as we are having great successes in discovering  and designing oligonucleotide therapies, and we are committed to R&D in  this field. This could be a major accelerant to highly-effective, personalized medicine” said Victor Galindo, an AI software engineer specializing in RNA therapeutics and one of the founders of Abzu.

The article introduces the difficulties with drug discovery (it’s high risk, time consuming, and expensive) and new computational modelling methods (like machine learning) that are being used to mitigate R&D risk. It is a light, high-level read for non-scientists: excellent for those who want an introduction to the pharmaceutical industry and the new technologies that are advancing science.

“Abzu's QLattice® was named as one of the machine learning technologies used to identify targets and drug candidates to make new medicines safer and more effective. The QLattice is highlighted for its unique explainability, which provides enormous benefits to drug discovery, especially oligonucleotide-based medicines”, he adds.